Abstract:Protein homeostasis (proteostasis) requires the timely degradation of misfolded proteins and their aggregates by protein quality control (PQC), of which molecular chaperones are an essential component. Compared with other cell types, PQC in neurons is particularly challenging because they have a unique cellular structure with long extensions. Making it worse, neurons are postmitotic, i.e., cannot dilute toxic substances by division, and, thus, are highly sensitive to misfolded proteins, especially as they age. Failure in PQC is often associated with neurodegenerative diseases, such as Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), and prion disease. In fact, many neurodegenerative diseases are considered to be protein misfolding disorders. To prevent the accumulation of disease-causing aggregates, neurons utilize a repertoire of chaperones that recognize misfolded proteins through exposed hydrophobic surfaces and assist their refolding. If such an effort fails, chaperones can facilitate the degradation of terminally misfolded proteins through either the ubiquitin (Ub)-proteasome system (UPS) or the autophagy-lysosome system (hereafter autophagy). If soluble, the substrates associated with chaperones, such as Hsp70, are ubiquitinated by Ub ligases and degraded through the proteasome complex. Some misfolded proteins carrying the KFERQ motif are recognized by the chaperone Hsc70 and delivered to the lysosomal lumen through a process called, chaperone-mediated autophagy (CMA). Aggregation-prone misfolded proteins that remain unprocessed are directed to macroautophagy in which cargoes are collected by adaptors, such as p62/SQSTM-1/Sequestosome-1, and delivered to the autophagosome for lysosomal degradation. The aggregates that have survived all these refolding/degradative processes can still be directly dissolved, i.e., disaggregated by chaperones. Studies have shown that molecular chaperones alleviate the pathogenic symptoms by neurodegeneration-causing protein aggregates. Chaperone-inducing drugs and anti-aggregation drugs are actively exploited for beneficial effects on symptoms of disease. Here, we discuss how chaperones protect misfolded proteins from aggregation and mediate the degradation of terminally misfolded proteins in collaboration with cellular degradative machinery. The topics also include therapeutic approaches to improve the expression and turnover of molecular chaperones and to develop anti-aggregation drugs.

The Role of Protein Quantity Control in Polyglutamine Spinocerebellar Ataxias

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Polyglutamine spinocerebellar ataxias — from genes to potential treatments

Polyglutamine spinocerebellar ataxias: emerging therapeutic targets

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion

Autophagy and Polyglutamine Disease

The Expanding Clinical Universe of Polyglutamine Disease.

Current Understanding on the Pathogenesis of Polyglutamine Diseases

The BAG2 and BAG5 Proteins Inhibit the Ubiquitination of Pathogenic Ataxin3-80Q.

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors

Molecular Mechanisms and Therapeutics for SCA17

Functional implications of paralog genes in polyglutamine spinocerebellar ataxias

Progress Study on the Mechanism of CAG Repeats Dynamic Mutation in Polyq Disease

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration

Molecular mechanisms underlying Spinocerebellar Ataxia 17 (SCA17) pathogenesis.

Polyglutamine Protein Trafficking and Neurodegeneration

Protein Quality Control Pathways at the Crossroad of Synucleinopathies

Small Molecules Inducing Autophagic Degradation of Expanded Polyglutamine Protein through Interaction with Both Mutant ATXN3 and LC3

Protein Quality Control by Molecular Chaperones in Neurodegeneration

Roles of Post-translational Modifications in Spinocerebellar Ataxias

Cerebellum-Enriched Protein Inpp5a Contributes To Selective Neuropathology In Mouse Model Of Spinocerebellar Ataxias Type 17